Defining mechanisms of genetic risk for pulmonary fibrosis. In collaboration with Drs. Timothy Blackwell, James Loyd and John Phillips at Vanderbilt, and other collaborators around the US, we utilize next-generation sequencing technologies to discover genes and genetic variants that contribute to risk for Idiopathic pulmonary fibrosis and other interstitial lung diseases.
Molecular mechanisms related to short-telomere associated pulmonary fibrosis. Work from our group and others has demonstrated that mutations in genes related to telomere biology are among the most commonly found in patients with pulmonary fibrosis. Using primary cell and animal models, we are investigating the mechanisms through which telomerase mutations and telomere dysfunction initiate and promote the development of pulmonary fibrosis.
Mechanisms of disease initiation and propagation in pulmonary fibrosis. In collaboration with Dr. Nicholas Banovich at the Translational Genomics Research Institute and Dr. Simon Mallal from the Vanderbilt Genetics Institute, we are utilizing single-cell technologies to determine the mechanisms and mediators of the early pathogenesis of pulmonary fibrosis.
A Phase Ib Trial of antiherpesvirus treatment in patients with Idiopathic Pulmonary Fibrosis. This Phase I randomized clinical trial is aimed at determining the safety and tolerability of valganciclovir added on to standard treatment in patients with a history of EBV or CMV infection. NCT02871401
Finding a pulmonary fibrosis gene. Directed by Dr. James Loyd, enrollment in the Vanderbilt pulmonary fibrosis registry is open to patients with pulmonary fibrosis or other interstitial lung diseases and their family members.